| Gene symbol | PDE6B | Synonyms | CSNB3, CSNBAD2, GMP-PDEbeta, PDEB, RP40, rd1 | Type of gene | protein-coding |
| Chromosome | 4 | Map location | 4p16.3 | dbXrefs | |
| Description | phosphodiesterase 6B | ||||
| GTO ID | GTC1812 |
| Trial ID | NCT03328130 |
| Disease | Retinitis Pigmentosa |
| Altered gene | PDE6B |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | AAV2/5-hPDE6B |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients With Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6β Expression |
| Year | 2017 |
| Country | United States |
| Company sponsor | eyeDNA Therapeutics |
| Other ID(s) | HORA-PDE6B-001|2016-001429-16 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||
|
|||||||